The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
2007

Stakeholder Views on Access to High-Cost Medicines in Australia

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): Lu Christine Y, Ritchie Jan, Williams Ken, Day Ric

Primary Institution: Harvard Medical School

Hypothesis

How can the access system for high-cost biological medicines in Australia be improved based on stakeholder opinions?

Conclusion

Stakeholders acknowledged the challenges of providing equitable access to high-cost medicines and suggested modifications to improve the Pharmaceutical Benefits Scheme.

Supporting Evidence

  • Stakeholders agreed that controlled access to expensive medicines is equitable.
  • Concerns were raised about the bureaucratic nature of the access scheme.
  • Participants suggested that broader stakeholder consultation is necessary.

Takeaway

This study talked to people about how to make it easier for patients to get expensive medicines. They found that while the system is fair, it could be better.

Methodology

Thirty-six semi-structured interviews were conducted and analyzed thematically.

Potential Biases

Some rheumatologists had advisory roles with pharmaceutical companies, which could influence their views.

Limitations

Insights into some managerial perspectives were not obtained as administrators declined to participate.

Participant Demographics

{"age_groups":{"18-29":1,"30-39":5,"40-49":8,"50-59":14,"60+":8},"sex":{"male":13,"female":23},"stakeholder_groups":{"rheumatologist":8,"patient":6,"government_advisor":5,"public_servant":8,"consumer_representative":5,"pharmaceutical_industry_representative":3,"clinical_nurse":1}}

Digital Object Identifier (DOI)

10.1186/1743-8462-4-26

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication